Press Releases

Date Title and Summary Additional Formats
Toggle Summary SAN DIEGO, March 01, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it will present at two conferences in March. Read All » View HTML
Toggle Summary Off-the-Shelf Natural Killer Cell Therapy Being Developed to Complement Standard-of-Care Monoclonal Antibody Treatment for Cancer First-of-Kind Product Candidate to be Manufactured from an Engineered Induced Pluripotent Stem Cell Line Intellectual Property Covering Compositions of Novel CD16 and Read All » View HTML
Toggle Summary SAN DIEGO, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will Read All » View HTML
Toggle Summary SAN DIEGO, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the first patient has been treated in its PROTECT clinical trial Read All » View HTML